Edition:
India

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

24.83USD
16 Jan 2018
Change (% chg)

-- (--)
Prev Close
$24.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
155,292
52-wk High
$25.72
52-wk Low
$11.14

Chart for

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development... (more)

Overall

Beta: --
Market Cap(Mil.): $792.65
Shares Outstanding(Mil.): 36.87
Dividend: --
Yield (%): --

Financials

BRIEF-Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8

* PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING Source text (http://bit.ly/2BGceJ2) Further company coverage:

19 Dec 2017

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC

28 Nov 2017

BRIEF-CytomX reports Q3 loss per share $‍0.28​

* CytomX announces third quarter 2017 financial results and operational progress

08 Nov 2017

BRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directors

* CytomX Therapeutics Inc appoints Charles S. Fuchs, M.D., MPH to board of directors Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Cytomx Therapeutics Q2 loss per share $ 0.69​

* Cytomx announces second quarter 2017 financial results and mid-year update webcast conference call

08 Aug 2017

Competitors

  Price Chg
AstraZeneca plc (AZN.L) 5,035.00 -14.00
GlaxoSmithKline plc (GSK.L) 1,365.60 +10.60
Merck & Co., Inc. (MRK.N) $62.07 +3.41
Novartis AG (NOVN.S) CHF83.68 +0.12
Pfizer Inc. (PFE.N) $36.60 +0.06
Roche Holding Ltd. (ROG.S) CHF234.15 -1.85
Roche Holding Ltd. (RO.S) CHF237.20 -2.20
Sanofi SA (SASY.PA) €73.40 0.00
ImmunoGen, Inc. (IMGN.OQ) $7.92 --
Seattle Genetics, Inc. (SGEN.OQ) $50.95 --

Earnings vs. Estimates